Endocrine Disruption Screening Market Growth & Opportunity 2028

According to our new research study on “Endocrine Disruption Screening Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Assay Type, Application, Source of Waste, Method, End-User and Geography,” the market is expected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The growth of the market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.

Many chemicals, both natural and man-made, have the potential to imitate or interfere with the endocrine system, which regulates the body’s hormones. These chemicals, known as endocrine disruptors, have been linked to developmental, reproductive, brain, immunological, and other disorders. Endocrine disruptors can be present in a variety of ordinary items, such as some plastic bottles and containers, metal food can liners, detergents, flame retardants, food, toys, cosmetics, and pesticides. Pesticides, chemicals, and environmental toxins are screened using a two-tiered method for their potential effect on the estrogen, androgen, and thyroid hormone systems by the endocrine disruptor screening.

Get Sample PDF Report at :- https://www.theinsightpartners.com/sample/TIPRE00025912/?utm_source=Social&utm_medum=10489

The growth of the market is attributed to growing research in the biotechnology sector and growing prevalence of endocrine disorders drive the market growth. However, the high cost of screening technology hampers the market growth.

Market leaders operating in the market have undertaken various organic and inorganic growth strategies. The endocrine disruptor screening market majorly consists of players like Creative Bioarray, Eurofins Scientific, Alpha Analytical, Inc., JRF Global, Xenometrix AG, SGS SA. Smithers, and Mérieux NutriSciences.

Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of erectile dysfunction, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.

North America held the largest share of the global endocrine disruption screening market in 2021. The US held the largest share of the North American market in 2021. The US market is expected to grow in the coming years due to the increasing adoption of technological advancements and the rising emphasis on the assessment of endocrine disruptor chemicals in agriculture pesticide use, sewage treatment plants, cosmetics and many other fields.

Creative Bioarray; Charles River Laboratories, Inc; Eurofins Scientific; Alpha Analytical, Inc.; JRF Global; Xenometrix AG; SGS SA; Smithers; and Mérieux NutriSciences are among the leading companies in the endocrine disruption screening market.

About The Insight Partners

The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialists in industries such as technology, media, food & beverages, chemicals & materials, and telecommunication.

Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.

Our research content is majorly focused toward market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, technology, products, services, etc., which helps our clients to gain a deeper analytical understanding of various research topics.

If you have any queries about this report or would like further information, please contact us:

Global: +1 646 491 9876

Asia Pacific: +91 20 6727 8686

Email: info@theinsightpartners.com